Search Menu
HIV Treatment Bulletin

HTB 13 December 2019 online

This final edition of HTB continues our reports from the 17th EACS conference recently held in Basel.

These include early data on a long acting (6-monthly) capsid inhibitor for MDR HIV, a review of dual therapy with dolutegravir/lamivudine, the lack of weight gain with doravirine, and an analysis on bone and renal changes in the ADVANCE study.

We also include a report on HIV loneliness from the recent workshop on HIV and Ageing.

ARV news includes: new UK access to doravirine, FDA submission for fostemsavir (but now on named patent access) and submission of a new paediatric formulation of dolutegravir.

Over the last few months i-Base has updated three treatment guides – see below – and we proudly distribute these free.

However, any loose change you have during the holiday season could find a worse home that the i-Base appeal.

Thank you to all our supporters who have contributed…